Martins Camilla de Almeida, Garcia Karoline Soares, Queiroz Natália Sousa Freita
Department of Gastroenterology, University of São Paulo School of Medicine, São Paulo, Brazil.
Hospital Santa Cruz, Curitiba, Brazil.
Front Med (Lausanne). 2022 Jul 28;9:864888. doi: 10.3389/fmed.2022.864888. eCollection 2022.
Inflammatory bowel disease (IBD) treatment targets have progressed over time from clinical response to clinical and endoscopic remission. Several data have shown a positive correlation between serum biologic drug concentrations and favorable therapeutic outcomes. Therapeutic drug monitoring (TDM) has evolved as an important approach for optimizing the use of immunobiologics, especially antitumor necrosis factor therapy, in patients with IBD. The use of TDM is supported by medical societies and IBD experts in different contexts; however, challenges remain due to knowledge gaps that limit the widespread use of it. The aim of this review is to assess the role of TDM in IBD, focusing on the implementation of this strategy in different scenarios and demonstrating the multi-utility aspects of this approach in clinical practice.
炎症性肠病（IBD）的治疗目标随着时间的推移已从临床反应发展到临床和内镜缓解。多项数据表明血清生物药物浓度与良好的治疗结果之间存在正相关。治疗药物监测（TDM）已发展成为优化免疫生物制剂使用的重要方法，尤其是在IBD患者中使用抗肿瘤坏死因子疗法。在不同情况下，医学协会和IBD专家都支持使用TDM；然而，由于知识空白限制了其广泛应用，挑战仍然存在。本综述的目的是评估TDM在IBD中的作用，重点关注该策略在不同场景中的实施，并展示该方法在临床实践中的多用途方面。
